PRA Health Sciences (PRAH) Given “Overweight” Rating at Barclays

PRA Health Sciences (NASDAQ:PRAH)‘s stock had its “overweight” rating reiterated by equities researchers at Barclays in a note issued to investors on Thursday, The Fly reports. They presently have a $115.00 target price on the medical research company’s stock. Barclays’ target price would indicate a potential upside of 9.71% from the company’s previous close.

Several other analysts also recently weighed in on PRAH. BidaskClub downgraded PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 27th. Zacks Investment Research upgraded PRA Health Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, May 1st. ValuEngine downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Monday, May 7th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $115.00 target price on shares of PRA Health Sciences in a research note on Friday, July 20th. One analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $100.36.

Get PRA Health Sciences alerts:

PRA Health Sciences opened at $104.82 on Thursday, Marketbeat.com reports. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 1.29. The stock has a market cap of $6.74 billion, a price-to-earnings ratio of 32.76, a PEG ratio of 1.62 and a beta of 0.54. PRA Health Sciences has a fifty-two week low of $73.05 and a fifty-two week high of $108.02.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, August 1st. The medical research company reported $1.00 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.04. The business had revenue of $722.84 million for the quarter, compared to the consensus estimate of $706.57 million. PRA Health Sciences had a return on equity of 23.06% and a net margin of 4.07%. The company’s quarterly revenue was up 35.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.79 EPS. research analysts forecast that PRA Health Sciences will post 3.82 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of PRAH. Stone Ridge Asset Management LLC purchased a new stake in shares of PRA Health Sciences in the fourth quarter worth about $211,000. Raymond James & Associates boosted its stake in shares of PRA Health Sciences by 56.4% in the fourth quarter. Raymond James & Associates now owns 21,318 shares of the medical research company’s stock worth $1,941,000 after buying an additional 7,684 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of PRA Health Sciences by 52.5% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,647 shares of the medical research company’s stock worth $150,000 after buying an additional 567 shares during the last quarter. LPL Financial LLC boosted its stake in shares of PRA Health Sciences by 15.7% in the fourth quarter. LPL Financial LLC now owns 11,667 shares of the medical research company’s stock worth $1,063,000 after buying an additional 1,581 shares during the last quarter. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of PRA Health Sciences in the fourth quarter worth about $2,078,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Trading Strategy Methods and Types

The Fly

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)